nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—SLC22A2—Cytarabine—lymphatic system cancer	0.42	0.584	CbGbCtD
Metoprolol—CYP2C19—Teniposide—lymphatic system cancer	0.136	0.19	CbGbCtD
Metoprolol—ABCB1—Mitoxantrone—lymphatic system cancer	0.077	0.107	CbGbCtD
Metoprolol—ABCB1—Vincristine—lymphatic system cancer	0.053	0.0737	CbGbCtD
Metoprolol—ABCB1—Methotrexate—lymphatic system cancer	0.0321	0.0447	CbGbCtD
Metoprolol—Vomiting—Mechlorethamine—lymphatic system cancer	0.000913	0.00325	CcSEcCtD
Metoprolol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000913	0.00324	CcSEcCtD
Metoprolol—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.000913	0.00324	CcSEcCtD
Metoprolol—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000911	0.00324	CcSEcCtD
Metoprolol—Rash—Mechlorethamine—lymphatic system cancer	0.000906	0.00322	CcSEcCtD
Metoprolol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000905	0.00322	CcSEcCtD
Metoprolol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0009	0.0032	CcSEcCtD
Metoprolol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000897	0.00319	CcSEcCtD
Metoprolol—Pneumonia—Vincristine—lymphatic system cancer	0.000897	0.00319	CcSEcCtD
Metoprolol—Depression—Vincristine—lymphatic system cancer	0.000889	0.00316	CcSEcCtD
Metoprolol—Weight increased—Mitoxantrone—lymphatic system cancer	0.000886	0.00315	CcSEcCtD
Metoprolol—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000873	0.0031	CcSEcCtD
Metoprolol—Feeling abnormal—Teniposide—lymphatic system cancer	0.000873	0.0031	CcSEcCtD
Metoprolol—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000866	0.00308	CcSEcCtD
Metoprolol—Sweating—Vincristine—lymphatic system cancer	0.000855	0.00304	CcSEcCtD
Metoprolol—Nausea—Mechlorethamine—lymphatic system cancer	0.000853	0.00303	CcSEcCtD
Metoprolol—Alopecia—Bleomycin—lymphatic system cancer	0.000849	0.00302	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000848	0.00301	CcSEcCtD
Metoprolol—Jaundice—Mitoxantrone—lymphatic system cancer	0.000846	0.00301	CcSEcCtD
Metoprolol—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.000844	0.003	CcSEcCtD
Metoprolol—Urticaria—Teniposide—lymphatic system cancer	0.000841	0.00299	CcSEcCtD
Metoprolol—Abdominal pain—Teniposide—lymphatic system cancer	0.000837	0.00298	CcSEcCtD
Metoprolol—Body temperature increased—Teniposide—lymphatic system cancer	0.000837	0.00298	CcSEcCtD
Metoprolol—Paraesthesia—Fludarabine—lymphatic system cancer	0.000836	0.00297	CcSEcCtD
Metoprolol—Hallucination—Carmustine—lymphatic system cancer	0.000834	0.00296	CcSEcCtD
Metoprolol—Sweating—Mitoxantrone—lymphatic system cancer	0.000832	0.00296	CcSEcCtD
Metoprolol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00083	0.00295	CcSEcCtD
Metoprolol—Oedema peripheral—Carmustine—lymphatic system cancer	0.000826	0.00294	CcSEcCtD
Metoprolol—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000824	0.00293	CcSEcCtD
Metoprolol—Dyspepsia—Fludarabine—lymphatic system cancer	0.000819	0.00291	CcSEcCtD
Metoprolol—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00081	0.00288	CcSEcCtD
Metoprolol—Visual impairment—Carmustine—lymphatic system cancer	0.000808	0.00287	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000804	0.00286	CcSEcCtD
Metoprolol—Fatigue—Fludarabine—lymphatic system cancer	0.000802	0.00285	CcSEcCtD
Metoprolol—Hallucination—Vincristine—lymphatic system cancer	0.000796	0.00283	CcSEcCtD
Metoprolol—Constipation—Fludarabine—lymphatic system cancer	0.000796	0.00283	CcSEcCtD
Metoprolol—Pain—Fludarabine—lymphatic system cancer	0.000796	0.00283	CcSEcCtD
Metoprolol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000794	0.00282	CcSEcCtD
Metoprolol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000787	0.0028	CcSEcCtD
Metoprolol—Eye disorder—Carmustine—lymphatic system cancer	0.000784	0.00278	CcSEcCtD
Metoprolol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000781	0.00278	CcSEcCtD
Metoprolol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00078	0.00277	CcSEcCtD
Metoprolol—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000779	0.00277	CcSEcCtD
Metoprolol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000767	0.00273	CcSEcCtD
Metoprolol—Asthenia—Teniposide—lymphatic system cancer	0.00076	0.0027	CcSEcCtD
Metoprolol—Pruritus—Teniposide—lymphatic system cancer	0.000749	0.00266	CcSEcCtD
Metoprolol—Arrhythmia—Carmustine—lymphatic system cancer	0.000749	0.00266	CcSEcCtD
Metoprolol—Leukopenia—Bleomycin—lymphatic system cancer	0.000748	0.00266	CcSEcCtD
Metoprolol—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.000747	0.00265	CcSEcCtD
Metoprolol—Cardiac disorder—Vincristine—lymphatic system cancer	0.000743	0.00264	CcSEcCtD
Metoprolol—Alopecia—Carmustine—lymphatic system cancer	0.000741	0.00263	CcSEcCtD
Metoprolol—Body temperature increased—Fludarabine—lymphatic system cancer	0.000736	0.00261	CcSEcCtD
Metoprolol—Mental disorder—Carmustine—lymphatic system cancer	0.000735	0.00261	CcSEcCtD
Metoprolol—Angiopathy—Vincristine—lymphatic system cancer	0.000726	0.00258	CcSEcCtD
Metoprolol—Diarrhoea—Teniposide—lymphatic system cancer	0.000725	0.00257	CcSEcCtD
Metoprolol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000721	0.00256	CcSEcCtD
Metoprolol—Chest pain—Bleomycin—lymphatic system cancer	0.000712	0.00253	CcSEcCtD
Metoprolol—Alopecia—Vincristine—lymphatic system cancer	0.000707	0.00251	CcSEcCtD
Metoprolol—Coma—Methotrexate—lymphatic system cancer	0.000707	0.00251	CcSEcCtD
Metoprolol—Mental disorder—Vincristine—lymphatic system cancer	0.000701	0.00249	CcSEcCtD
Metoprolol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000696	0.00247	CcSEcCtD
Metoprolol—Alopecia—Mitoxantrone—lymphatic system cancer	0.000689	0.00245	CcSEcCtD
Metoprolol—Confusional state—Bleomycin—lymphatic system cancer	0.000688	0.00245	CcSEcCtD
Metoprolol—Vision blurred—Carmustine—lymphatic system cancer	0.000688	0.00244	CcSEcCtD
Metoprolol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000686	0.00244	CcSEcCtD
Metoprolol—Oedema—Bleomycin—lymphatic system cancer	0.000682	0.00243	CcSEcCtD
Metoprolol—Vomiting—Teniposide—lymphatic system cancer	0.000673	0.00239	CcSEcCtD
Metoprolol—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000668	0.00237	CcSEcCtD
Metoprolol—Asthenia—Fludarabine—lymphatic system cancer	0.000668	0.00237	CcSEcCtD
Metoprolol—Rash—Teniposide—lymphatic system cancer	0.000668	0.00237	CcSEcCtD
Metoprolol—Dermatitis—Teniposide—lymphatic system cancer	0.000667	0.00237	CcSEcCtD
Metoprolol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000664	0.00236	CcSEcCtD
Metoprolol—Headache—Teniposide—lymphatic system cancer	0.000663	0.00236	CcSEcCtD
Metoprolol—Pruritus—Fludarabine—lymphatic system cancer	0.000659	0.00234	CcSEcCtD
Metoprolol—Leukopenia—Carmustine—lymphatic system cancer	0.000653	0.00232	CcSEcCtD
Metoprolol—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000645	0.00229	CcSEcCtD
Metoprolol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000639	0.00227	CcSEcCtD
Metoprolol—Photosensitivity—Methotrexate—lymphatic system cancer	0.000639	0.00227	CcSEcCtD
Metoprolol—Hypotension—Bleomycin—lymphatic system cancer	0.000638	0.00227	CcSEcCtD
Metoprolol—Diarrhoea—Fludarabine—lymphatic system cancer	0.000637	0.00226	CcSEcCtD
Metoprolol—Hypertension—Carmustine—lymphatic system cancer	0.00063	0.00224	CcSEcCtD
Metoprolol—Nausea—Teniposide—lymphatic system cancer	0.000629	0.00224	CcSEcCtD
Metoprolol—Vertigo—Vincristine—lymphatic system cancer	0.000626	0.00222	CcSEcCtD
Metoprolol—Leukopenia—Vincristine—lymphatic system cancer	0.000624	0.00222	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000622	0.00221	CcSEcCtD
Metoprolol—Chest pain—Carmustine—lymphatic system cancer	0.000621	0.00221	CcSEcCtD
Metoprolol—Anxiety—Carmustine—lymphatic system cancer	0.000619	0.0022	CcSEcCtD
Metoprolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.000613	0.00218	CcSEcCtD
Metoprolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.000608	0.00216	CcSEcCtD
Metoprolol—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000607	0.00216	CcSEcCtD
Metoprolol—Hypertension—Vincristine—lymphatic system cancer	0.000602	0.00214	CcSEcCtD
Metoprolol—Confusional state—Carmustine—lymphatic system cancer	0.000601	0.00213	CcSEcCtD
Metoprolol—Oedema—Carmustine—lymphatic system cancer	0.000596	0.00212	CcSEcCtD
Metoprolol—Visual disturbance—Methotrexate—lymphatic system cancer	0.000592	0.00211	CcSEcCtD
Metoprolol—Vomiting—Fludarabine—lymphatic system cancer	0.000592	0.0021	CcSEcCtD
Metoprolol—Rash—Fludarabine—lymphatic system cancer	0.000587	0.00209	CcSEcCtD
Metoprolol—Dermatitis—Fludarabine—lymphatic system cancer	0.000586	0.00208	CcSEcCtD
Metoprolol—Hypertension—Mitoxantrone—lymphatic system cancer	0.000586	0.00208	CcSEcCtD
Metoprolol—Pain—Bleomycin—lymphatic system cancer	0.000584	0.00207	CcSEcCtD
Metoprolol—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000583	0.00207	CcSEcCtD
Metoprolol—Headache—Fludarabine—lymphatic system cancer	0.000583	0.00207	CcSEcCtD
Metoprolol—Tachycardia—Carmustine—lymphatic system cancer	0.000581	0.00207	CcSEcCtD
Metoprolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.000578	0.00205	CcSEcCtD
Metoprolol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000578	0.00205	CcSEcCtD
Metoprolol—Anxiety—Mitoxantrone—lymphatic system cancer	0.000576	0.00205	CcSEcCtD
Metoprolol—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000573	0.00204	CcSEcCtD
Metoprolol—Oedema—Vincristine—lymphatic system cancer	0.000569	0.00202	CcSEcCtD
Metoprolol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000562	0.002	CcSEcCtD
Metoprolol—Confusional state—Mitoxantrone—lymphatic system cancer	0.000558	0.00198	CcSEcCtD
Metoprolol—Nervous system disorder—Vincristine—lymphatic system cancer	0.000558	0.00198	CcSEcCtD
Metoprolol—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000557	0.00198	CcSEcCtD
Metoprolol—Hypotension—Carmustine—lymphatic system cancer	0.000557	0.00198	CcSEcCtD
Metoprolol—Oedema—Mitoxantrone—lymphatic system cancer	0.000554	0.00197	CcSEcCtD
Metoprolol—Nausea—Fludarabine—lymphatic system cancer	0.000553	0.00196	CcSEcCtD
Metoprolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00055	0.00195	CcSEcCtD
Metoprolol—Shock—Mitoxantrone—lymphatic system cancer	0.000545	0.00194	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000543	0.00193	CcSEcCtD
Metoprolol—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000542	0.00193	CcSEcCtD
Metoprolol—Urticaria—Bleomycin—lymphatic system cancer	0.000542	0.00193	CcSEcCtD
Metoprolol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00054	0.00192	CcSEcCtD
Metoprolol—Body temperature increased—Bleomycin—lymphatic system cancer	0.000539	0.00192	CcSEcCtD
Metoprolol—Insomnia—Carmustine—lymphatic system cancer	0.000539	0.00191	CcSEcCtD
Metoprolol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000538	0.00191	CcSEcCtD
Metoprolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000535	0.0019	CcSEcCtD
Metoprolol—Paraesthesia—Carmustine—lymphatic system cancer	0.000535	0.0019	CcSEcCtD
Metoprolol—Mood swings—Methotrexate—lymphatic system cancer	0.000532	0.00189	CcSEcCtD
Metoprolol—Hypotension—Vincristine—lymphatic system cancer	0.000531	0.00189	CcSEcCtD
Metoprolol—Dyspnoea—Carmustine—lymphatic system cancer	0.000531	0.00189	CcSEcCtD
Metoprolol—Somnolence—Carmustine—lymphatic system cancer	0.00053	0.00188	CcSEcCtD
Metoprolol—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000518	0.00184	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000518	0.00184	CcSEcCtD
Metoprolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.000517	0.00184	CcSEcCtD
Metoprolol—Insomnia—Vincristine—lymphatic system cancer	0.000514	0.00183	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000514	0.00183	CcSEcCtD
Metoprolol—Paraesthesia—Vincristine—lymphatic system cancer	0.000511	0.00181	CcSEcCtD
Metoprolol—Pain—Carmustine—lymphatic system cancer	0.000509	0.00181	CcSEcCtD
Metoprolol—Constipation—Carmustine—lymphatic system cancer	0.000509	0.00181	CcSEcCtD
Metoprolol—Breast disorder—Methotrexate—lymphatic system cancer	0.000507	0.0018	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000505	0.00179	CcSEcCtD
Metoprolol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000503	0.00179	CcSEcCtD
Metoprolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000497	0.00177	CcSEcCtD
Metoprolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000494	0.00175	CcSEcCtD
Metoprolol—Somnolence—Mitoxantrone—lymphatic system cancer	0.000492	0.00175	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000491	0.00174	CcSEcCtD
Metoprolol—Feeling abnormal—Carmustine—lymphatic system cancer	0.000491	0.00174	CcSEcCtD
Metoprolol—Fatigue—Vincristine—lymphatic system cancer	0.00049	0.00174	CcSEcCtD
Metoprolol—Asthenia—Bleomycin—lymphatic system cancer	0.00049	0.00174	CcSEcCtD
Metoprolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000487	0.00173	CcSEcCtD
Metoprolol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000487	0.00173	CcSEcCtD
Metoprolol—Pain—Vincristine—lymphatic system cancer	0.000486	0.00173	CcSEcCtD
Metoprolol—Constipation—Vincristine—lymphatic system cancer	0.000486	0.00173	CcSEcCtD
Metoprolol—Pruritus—Bleomycin—lymphatic system cancer	0.000483	0.00172	CcSEcCtD
Metoprolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.000477	0.0017	CcSEcCtD
Metoprolol—Pain—Mitoxantrone—lymphatic system cancer	0.000474	0.00168	CcSEcCtD
Metoprolol—Constipation—Mitoxantrone—lymphatic system cancer	0.000474	0.00168	CcSEcCtD
Metoprolol—Abdominal pain—Carmustine—lymphatic system cancer	0.000471	0.00167	CcSEcCtD
Metoprolol—Body temperature increased—Carmustine—lymphatic system cancer	0.000471	0.00167	CcSEcCtD
Metoprolol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000465	0.00165	CcSEcCtD
Metoprolol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000456	0.00162	CcSEcCtD
Metoprolol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000453	0.00161	CcSEcCtD
Metoprolol—Body temperature increased—Vincristine—lymphatic system cancer	0.00045	0.0016	CcSEcCtD
Metoprolol—Abdominal pain—Vincristine—lymphatic system cancer	0.00045	0.0016	CcSEcCtD
Metoprolol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000447	0.00159	CcSEcCtD
Metoprolol—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000443	0.00157	CcSEcCtD
Metoprolol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00044	0.00156	CcSEcCtD
Metoprolol—Hypersensitivity—Carmustine—lymphatic system cancer	0.000439	0.00156	CcSEcCtD
Metoprolol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000438	0.00156	CcSEcCtD
Metoprolol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000438	0.00156	CcSEcCtD
Metoprolol—Pneumonia—Methotrexate—lymphatic system cancer	0.000435	0.00155	CcSEcCtD
Metoprolol—Vomiting—Bleomycin—lymphatic system cancer	0.000434	0.00154	CcSEcCtD
Metoprolol—Depression—Methotrexate—lymphatic system cancer	0.000431	0.00153	CcSEcCtD
Metoprolol—Rash—Bleomycin—lymphatic system cancer	0.00043	0.00153	CcSEcCtD
Metoprolol—Dermatitis—Bleomycin—lymphatic system cancer	0.00043	0.00153	CcSEcCtD
Metoprolol—Asthenia—Carmustine—lymphatic system cancer	0.000427	0.00152	CcSEcCtD
Metoprolol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000421	0.00149	CcSEcCtD
Metoprolol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000419	0.00149	CcSEcCtD
Metoprolol—Sweating—Methotrexate—lymphatic system cancer	0.000415	0.00147	CcSEcCtD
Metoprolol—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000409	0.00145	CcSEcCtD
Metoprolol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000408	0.00145	CcSEcCtD
Metoprolol—Asthenia—Vincristine—lymphatic system cancer	0.000408	0.00145	CcSEcCtD
Metoprolol—Diarrhoea—Carmustine—lymphatic system cancer	0.000408	0.00145	CcSEcCtD
Metoprolol—Nausea—Bleomycin—lymphatic system cancer	0.000405	0.00144	CcSEcCtD
Metoprolol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000404	0.00143	CcSEcCtD
Metoprolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.000397	0.00141	CcSEcCtD
Metoprolol—Dizziness—Carmustine—lymphatic system cancer	0.000394	0.0014	CcSEcCtD
Metoprolol—Diarrhoea—Vincristine—lymphatic system cancer	0.000389	0.00138	CcSEcCtD
Metoprolol—Hepatitis—Methotrexate—lymphatic system cancer	0.000388	0.00138	CcSEcCtD
Metoprolol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000379	0.00135	CcSEcCtD
Metoprolol—Vomiting—Carmustine—lymphatic system cancer	0.000379	0.00135	CcSEcCtD
Metoprolol—Dizziness—Vincristine—lymphatic system cancer	0.000376	0.00134	CcSEcCtD
Metoprolol—Rash—Carmustine—lymphatic system cancer	0.000376	0.00133	CcSEcCtD
Metoprolol—Dermatitis—Carmustine—lymphatic system cancer	0.000375	0.00133	CcSEcCtD
Metoprolol—Visual impairment—Methotrexate—lymphatic system cancer	0.000374	0.00133	CcSEcCtD
Metoprolol—Headache—Carmustine—lymphatic system cancer	0.000373	0.00133	CcSEcCtD
Metoprolol—Eye disorder—Methotrexate—lymphatic system cancer	0.000363	0.00129	CcSEcCtD
Metoprolol—Tinnitus—Methotrexate—lymphatic system cancer	0.000362	0.00129	CcSEcCtD
Metoprolol—Vomiting—Vincristine—lymphatic system cancer	0.000362	0.00128	CcSEcCtD
Metoprolol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00036	0.00128	CcSEcCtD
Metoprolol—Rash—Vincristine—lymphatic system cancer	0.000359	0.00127	CcSEcCtD
Metoprolol—Dermatitis—Vincristine—lymphatic system cancer	0.000358	0.00127	CcSEcCtD
Metoprolol—Headache—Vincristine—lymphatic system cancer	0.000356	0.00127	CcSEcCtD
Metoprolol—Nausea—Carmustine—lymphatic system cancer	0.000354	0.00126	CcSEcCtD
Metoprolol—Angiopathy—Methotrexate—lymphatic system cancer	0.000352	0.00125	CcSEcCtD
Metoprolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000352	0.00125	CcSEcCtD
Metoprolol—Immune system disorder—Methotrexate—lymphatic system cancer	0.000351	0.00125	CcSEcCtD
Metoprolol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00035	0.00124	CcSEcCtD
Metoprolol—Rash—Mitoxantrone—lymphatic system cancer	0.000349	0.00124	CcSEcCtD
Metoprolol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000349	0.00124	CcSEcCtD
Metoprolol—Headache—Mitoxantrone—lymphatic system cancer	0.000347	0.00123	CcSEcCtD
Metoprolol—Alopecia—Methotrexate—lymphatic system cancer	0.000343	0.00122	CcSEcCtD
Metoprolol—Mental disorder—Methotrexate—lymphatic system cancer	0.00034	0.00121	CcSEcCtD
Metoprolol—Nausea—Vincristine—lymphatic system cancer	0.000338	0.0012	CcSEcCtD
Metoprolol—Dysgeusia—Methotrexate—lymphatic system cancer	0.000331	0.00118	CcSEcCtD
Metoprolol—Nausea—Mitoxantrone—lymphatic system cancer	0.000329	0.00117	CcSEcCtD
Metoprolol—Vision blurred—Methotrexate—lymphatic system cancer	0.000319	0.00113	CcSEcCtD
Metoprolol—Vertigo—Methotrexate—lymphatic system cancer	0.000304	0.00108	CcSEcCtD
Metoprolol—Leukopenia—Methotrexate—lymphatic system cancer	0.000303	0.00108	CcSEcCtD
Metoprolol—Chest pain—Methotrexate—lymphatic system cancer	0.000288	0.00102	CcSEcCtD
Metoprolol—Arthralgia—Methotrexate—lymphatic system cancer	0.000288	0.00102	CcSEcCtD
Metoprolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000286	0.00102	CcSEcCtD
Metoprolol—Confusional state—Methotrexate—lymphatic system cancer	0.000278	0.000989	CcSEcCtD
Metoprolol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000271	0.000962	CcSEcCtD
Metoprolol—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00027	0.00096	CcSEcCtD
Metoprolol—Skin disorder—Methotrexate—lymphatic system cancer	0.000268	0.000952	CcSEcCtD
Metoprolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000267	0.000948	CcSEcCtD
Metoprolol—Hypotension—Methotrexate—lymphatic system cancer	0.000258	0.000916	CcSEcCtD
Metoprolol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000251	0.000893	CcSEcCtD
Metoprolol—Insomnia—Methotrexate—lymphatic system cancer	0.00025	0.000887	CcSEcCtD
Metoprolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000248	0.00088	CcSEcCtD
Metoprolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000246	0.000874	CcSEcCtD
Metoprolol—Somnolence—Methotrexate—lymphatic system cancer	0.000245	0.000872	CcSEcCtD
Metoprolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000243	0.000863	CcSEcCtD
Metoprolol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000238	0.000847	CcSEcCtD
Metoprolol—Fatigue—Methotrexate—lymphatic system cancer	0.000238	0.000845	CcSEcCtD
Metoprolol—Pain—Methotrexate—lymphatic system cancer	0.000236	0.000838	CcSEcCtD
Metoprolol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000227	0.000808	CcSEcCtD
Metoprolol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000226	0.000802	CcSEcCtD
Metoprolol—Urticaria—Methotrexate—lymphatic system cancer	0.000219	0.000779	CcSEcCtD
Metoprolol—Abdominal pain—Methotrexate—lymphatic system cancer	0.000218	0.000775	CcSEcCtD
Metoprolol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000218	0.000775	CcSEcCtD
Metoprolol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000203	0.000722	CcSEcCtD
Metoprolol—Asthenia—Methotrexate—lymphatic system cancer	0.000198	0.000703	CcSEcCtD
Metoprolol—Pruritus—Methotrexate—lymphatic system cancer	0.000195	0.000694	CcSEcCtD
Metoprolol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000189	0.000671	CcSEcCtD
Metoprolol—Dizziness—Methotrexate—lymphatic system cancer	0.000182	0.000648	CcSEcCtD
Metoprolol—Vomiting—Methotrexate—lymphatic system cancer	0.000175	0.000623	CcSEcCtD
Metoprolol—Rash—Methotrexate—lymphatic system cancer	0.000174	0.000618	CcSEcCtD
Metoprolol—Dermatitis—Methotrexate—lymphatic system cancer	0.000174	0.000618	CcSEcCtD
Metoprolol—Headache—Methotrexate—lymphatic system cancer	0.000173	0.000614	CcSEcCtD
Metoprolol—Nausea—Methotrexate—lymphatic system cancer	0.000164	0.000582	CcSEcCtD
